MSH6 and endometrial carcinoma: The 2021 ESGO guidelines recommend that the molecular classification, including three immunohistochemical markers (p53, MSH6, and PMS2) and one molecular test (mutation analysis of the exonuclease domain of POLE) should be encouraged in all endometrial carcinomas, although data regarding integrated molecular and histological prognostic factors remain scarce.2, 36